NRx Pharmaceuticals (NRXP) Q4 2024 earnings summary

Executive summary

• Transitioned from a pure R&D model to a revenue-generating healthcare company, aiming for profitability by end of 2025.

• Initiated NDA filing for NRX-100 (IV ketamine) for suicidal depression and preparing NDA for NRX-101 (bipolar depression with akathisia risk), both with anticipated PDUFA dates before Dec 31, 2025.

• Accepted non-binding licensing terms for NRX-100, potentially yielding over $300 million in milestones and double-digit royalties.

• Established Hope Therapeutics as a wholly-owned subsidiary to operate interventional psychiatry clinics, signing LOIs to acquire three profitable clinics and negotiating for additional centers.

• Regained NASDAQ compliance and substantially reduced operating costs year-over-year.

Financial highlights

• Reduced loss from operations by 33.5% to $18.5 million for 2024, compared to $27.8 million in 2023.

• Q4 2024 loss from operations reduced to $2.4 million from $4.4 million in Q4 2023, a 45% improvement.

• Research and development expenses decreased by $7.2 million (53.6%) to $6.2 million, mainly due to the conclusion of a major clinical trial.

• General administrative expenses decreased by $7.7 million to $13.5 million, driven by lower insurance and employee costs.

• Ended 2024 with $1.4 million in cash; raised an additional $8.5 million in January 2025, expected to fund operations through at least end of 2025.

Outlook and guidance

• Targeting FDA approval (PDUFA dates) for NRX-100 and NRX-101 before Dec 31, 2025.

• Forecasting profitability by end of 2025, driven by Hope Therapeutics' revenue and drug sales.

• Plans to spin out Hope Therapeutics to shareholders in a tax-free manner once conditions allow.

• Anticipates further clinic acquisitions, aiming for 15-20 facilities in Florida by year-end 2025.

• Plans to file an ANDA for preservative-free ketamine in 2Q25.